Pain News and Research

Latest Pain News and Research

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Celgene International Sàrl, a subsidiary of Celgene Corporation today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease at EULAR, the European Congress of Rheumatology annual meeting in Madrid.

14 Jun 2013

Overweight, obese ERA patients require twice as much drug therapy to achieve successful remission

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that overweight and obese patients are less likely to achieve successful remission in early rheumatoid arthritis compared to those of normal weight.

14 Jun 2013

Ischaemic heart disease patients at risk after 1 week of treatment

New study data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate a high prevalence of NSAID prescriptions in patients at risk of ischaemic heart disease.

14 Jun 2013

Novel antibody biomarkers could significantly improve diagnosis in RA, study shows

Data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, show that novel antibody biomarkers could significantly improve diagnosis in rheumatoid arthritis.

14 Jun 2013

Data demonstrate benefits of nurse-led programme on patient self-management of RA

Data first presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism demonstrate the benefits of a nurse-led programme on patient self-management and the management of rheumatoid arthritis co-morbidities.

14 Jun 2013

Pathway Genomics announces launch of inherited cancer panel with BRCA1 and BRCA2

Pathway Genomics, a genetic testing laboratory on the forefront of bringing physicians a broad genetic testing portfolio covering a wide range of diseases, announces the pending launch of its inherited cancer panel with BRCA1 and BRCA2.

14 Jun 2013

Study provides important new resources to advance suicide prevention

A University of British Columbia study sheds important new light on why people attempt suicide and provides the first scientifically tested measure for evaluating the motivations for suicide.

14 Jun 2013

IQWiG tests suitability of AHP method for identifying preferences of patients regarding treatment goals

It is more important to patients suffering from depression that they show a noticeable response to treatment in the first place than being completely cured. It is exactly the opposite in physicians treating people with this disease: they consider remission to have higher priority than response.

14 Jun 2013

Nervous system and nerve-growth factor play major role in arthritis

Arthritis is a debilitating disorder affecting one in 10 Canadians, with pain caused by inflammation and damage to joints.

14 Jun 2013

Xgeva receives FDA approval for treating giant cell tumor of the bone

The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone, a rare and usually non-cancerous tumor.

14 Jun 2013

NACC recommendations address established pain therapies and preview potential future advances

Recommendations of the Neuromodulation Appropriateness Consensus Committee (NACC), announced at the 11th World Congress of the International Neuromodulation Society (INS), address established therapies and preview emerging and potential future advances.

13 Jun 2013

Researchers create guidelines to reduce staph infections after surgery

Staph infections in hospitals are a serious concern, so much so that the term Methicillin-resistant Staphylococcus aureus is as commonly known as MRI. Far less known is that in many of these cases, patients are infecting themselves.

13 Jun 2013

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA).

13 Jun 2013

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

New PSUMMIT 2 data first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, further demonstrate the efficacy of ustekinumab in Psoriatic Arthritis (PsA).

13 Jun 2013

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks.

13 Jun 2013

Study demonstrates efficacy of ARASHI method at evaluating radiographic joint damage in RA

A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrates the efficacy of the ARASHI method at evaluating radiographic (X-ray) joint damage in RA.

13 Jun 2013

Study reveals 83% of teens have unsupervised access to prescription medications

A new study in the Journal of Adolescent Health found that 83.4 percent of teens had unsupervised access to their prescription medications at home including 73.7 percent taking pain relief, anti-anxiety, stimulant and sedative medications that have the potential for abuse.

13 Jun 2013

Using Swiss ball improves walking performance and muscle strength in AS patients

A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrates that progressive muscle strengthening using a Swiss ball is effective in improving muscle strength and walking performance in patients with Ankylosing Spondylitis (AS).

13 Jun 2013

Society of Interventional Radiology releases Updates in Interventional Radiology 2013

The Society of Interventional Radiology announces the release of "Updates in Interventional Radiology 2013," a concise reference of the current literature most relevant to the specialty.

13 Jun 2013

Constella® (linaclotide), for the symptomatic treatment of Irritable Bowel Syndrome with Constipation (IBS-C), is now available in Germany, UK and Nordic countries

Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced the launch of Constella® (linaclotide 290mcg capsules once daily), the first approved prescription therapy in a new class of treatments for adults suffering from moderate to severe IBS-C,(1) in Europe. Constella® is now available in Germany, the UK and Nordic countries and is expected to be launched in several other European countries in 2013.

13 Jun 2013

Pain News and Research

Latest Pain News and Research

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Overweight, obese ERA patients require twice as much drug therapy to achieve successful remission

Ischaemic heart disease patients at risk after 1 week of treatment

Novel antibody biomarkers could significantly improve diagnosis in RA, study shows

Data demonstrate benefits of nurse-led programme on patient self-management of RA

Pathway Genomics announces launch of inherited cancer panel with BRCA1 and BRCA2

Study provides important new resources to advance suicide prevention

IQWiG tests suitability of AHP method for identifying preferences of patients regarding treatment goals

Nervous system and nerve-growth factor play major role in arthritis

Xgeva receives FDA approval for treating giant cell tumor of the bone

NACC recommendations address established pain therapies and preview potential future advances

Researchers create guidelines to reduce staph infections after surgery

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Study demonstrates efficacy of ARASHI method at evaluating radiographic joint damage in RA

Study reveals 83% of teens have unsupervised access to prescription medications

Using Swiss ball improves walking performance and muscle strength in AS patients

Society of Interventional Radiology releases Updates in Interventional Radiology 2013

Constella® (linaclotide), for the symptomatic treatment of Irritable Bowel Syndrome with Constipation (IBS-C), is now available in Germany, UK and Nordic countries

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Pain News and Research

Latest Pain News and Research

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Newsletters you may be interested in